Stockreport

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder [Yahoo! Finance]

Jaguar Health, Inc.  (JAGX) 
US:NASDAQ Investor Relations: jaguarhealth.gcs-web.com/investor-overview
PDF two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle Ea [Read more]